Synta collaborates on Hsp90 inhibitor study; Cangene CFO departs in ongoing restructuring; AVEO publishes tivozanib data;

@FierceBiotech: Experts puzzled over low turnout in cancer trials. Story | Follow @FierceBiotech

@JohnCFierce: The ultimate virtual biotech? Halo scouts for funds to finance mid-stage DMD trial. Not a genetic fix, either. Piece | Follow @JohnCFierce

@RyanMFierce:  Google VC doubles down on Big Data after biotech bets. Article | Follow @RyanMFierce

> Synta Pharmaceuticals announced a pact to collaborate with the Multiple Myeloma Research Consortium on a clinical trial of its second-gen Hsp90 inhibitor. The Multiple Myeloma Research Foundation is providing up to a million dollars for the study. Report

> In an ongoing restructuring, Canada's Cangene announced that its CFO has left the company. In January, Cangene axed 120 workers. Story

> Aveo Pharmaceuticals says it has published the results from a successful Phase II clinical trial evaluating the efficacy and safety of tivozanib in 272 patients with advanced renal cell carcinoma in the Journal of Clinical Oncology. Release

Pharma News

@FiercePharma: Budget cuts in Europe squeeze Roche's regional sales 4%, but US growth of 6% more than offsets it--ReutersNews | Follow @FiercePharma

> J&J's $1.2B Risperdal fine 'ups the ante' for other cases. Story

> Roche sales flat for Q1, but cancer meds shine. Report

> Reuters: Watson aims for Actavis deal this month. Item

> Sales-rep overtime steps into Supreme Court. Article

Medical Devices News

 @FierceMedDev: Quest Diagnostics Names Steve Rusckowski as President and CEO. Release | Follow @FierceMedDev

> Quest snags Philips Healthcare head as new CEO. News

> FDA panel wants U-Systems' breast ultrasound approved. Article

> Irish researchers look to up angioplasty success rates. Item

> Sony slashes jobs, boosts med equipment focus. Story

Manufacturing News

> Surya Pharmaceuticals closes 2 Indian API plants. Story

> 3 big animal drugmakers volunteer to change labels. News

> Some supply issues expected from Teva plant in Croatia. More

> Hospira taps drug industry veteran to oversee operations. Article

CRO News

> FDA issues warning to BioMed IRB over its practices. More

> eResearch Technology goes private as lawyers investigate acquisition. Article

> Experts puzzled over low turnout in cancer trials. Story

Vaccines News

> Intellect Neurosciences chases Holy Grail of Alzheimer's: a preventive vaccine. Commentary

> GAVI signs deal for diarrhea vax for world's poorest. Article

> Asthma vaccine hopes rise in preclinical trials. Story

> Vaccine approach could trick immune system. Item

> 'Universal' cancer vaccine not miraculous but could bring hope. More

And Finally... A new study from Michigan State concludes that almost a third of all injuries sustained by college athletes is the result of "overuse." Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.